Topic:
Supply Chain and Manufacturing
Latest Headlines
Latest Headlines
Women want Apotex to pay for unwanted pregnancies
Forty-five women who had turned to Apotex for contraceptives to avoid having children are now looking to the Canadian drugmaker to help them pay for their babies, or their abortions, after they ended up pregnant.
Ranbaxy's rocky road ahead after $500M settlement
How will Ranbaxy Laboratories' $500 million manufacturing settlement affect its business in the U.S.? Take your pick: It will either revive the company's exports to the States, or it will drag down its U.S. reputation, adding insult to the injury of $500 million in already-lost sales.
Novartis reverses course on Swiss OTC plant that was to be closed
Novartis is doing a complete U-turn on an OTC plant in Switzerland that 18 months ago was going to get the old heave-ho along with the people who worked there. Now the drugmaker says it will invest €150 million in the facility and anoint it a center of excellence.
Ipsen warns of shortages of its orphan drug Increlex
French drugmaker Ipsen says shortages of its orphan drug Increlex appear inevitable because of ongoing issues at Lonza plant in the U.S. The drug is used to treat a rare condition in children called IGF-1 deficiency, which results in them being very short for their age.
U.S. feds launch probe into AstraZeneca plant in U.K.
U.S. federal investigators have taken an interest in manufacturing at an AstraZeneca plant in England, but the company is remaining mum about what precisely they want to know.
Feds nail key player in counterfeit Avastin probe
For more than a year, U.S. authorities have been tightening a noose around Internet pharmacy company Canada Drugs, which reportedly was the source of counterfeit Avastin shipped last year to doctors.
J&J releases more Doxil to the market
Johnson & Johnson and the FDA sprang into action in 2011 when J&J's popular chemo drug Doxil became hard to get because of problems with the contract manufacturer. But it also figured out a process by which it could have it manufactured at one plant and finished at another.
Odors lead to back order for Pfizer's Levoxyl
Drugs being pulled off of shelves because of bad odors generally have no health risks associated with them, but they cost drugmakers money and consumers inconvenience.
Pfizer fails to block $142M Neurontin award, faces 2 more suits
Pfizer's potential liability on off-label Neurontin use just grew: A U.S. appeals court in Boston upheld a $142 million verdict in one lawsuit and reinstated two others that had been tossed out by lower courts--including a class action that could allow hundreds of health plans to pursue claims against the company
Lilly bets on new insulin products with $180M plant addition
Eli Lilly has made a huge bet on insulin to help it maneuver past patent losses for drugs like antidepressant Cymbalta which falls off this year. It has four new products in development, including one that could give Sanofi's Lantus a run for it money.
